GILD vs. BIIB, AMGN, MRNA, ARGX, BNTX, HCA, GSK, BMY, ZTS, and MCK
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Biogen (BIIB), Amgen (AMGN), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), HCA Healthcare (HCA), GSK (GSK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and McKesson (MCK). These companies are all part of the "medical" sector.
Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Biogen presently has a consensus price target of $290.92, suggesting a potential upside of 33.75%. Gilead Sciences has a consensus price target of $83.69, suggesting a potential upside of 29.19%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Biogen is more favorable than Gilead Sciences.
In the previous week, Biogen had 2 more articles in the media than Gilead Sciences. MarketBeat recorded 34 mentions for Biogen and 32 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.73 beat Biogen's score of 0.39 indicating that Biogen is being referred to more favorably in the media.
Gilead Sciences has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Biogen has a net margin of 12.07% compared to Biogen's net margin of 1.76%. Biogen's return on equity of 24.34% beat Gilead Sciences' return on equity.
Biogen has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
Gilead Sciences received 674 more outperform votes than Biogen when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 71.88% of users gave Biogen an outperform vote.
87.9% of Biogen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.6% of Biogen shares are owned by company insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Biogen beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gilead Sciences Competitors List
Related Companies and Tools
